An unbalanced increase in dietary omega-6 (n-6) polyunsaturated fatty acids (PUFA) and decrease in omega-3 (n-3) PUFA in the Western diet coincides with the global rise in chronic diseases. Whether n-6 and n-3 PUFA oppositely contribute to the development of chronic disease remains controversial. By using transgenic mice capable of synthesizing PUFA to eliminate confounding factors of diet, we show…
Read More
Genome-wide association studies (GWAS) have revealed risk alleles for ulcerative colitis (UC). To understand their cell type specificities and pathways of action, we generate an atlas of 366,650 cells from the colon mucosa of 18 UC patients and 12 healthy individuals, revealing 51 epithelial, stromal, and immune cell subsets, including BEST4 + enterocytes, microfold-like cells, and IL13RA2 + IL11 + inflammatory fibroblasts, which we associate with resistance to anti-TNF…
Read More
Tufts researchers discover a gene necessary for maintenance of healthy sleep in fruit flies, which might help understand human sleep. What keeps us awake—and helps us fall asleep? The answer is complex, but involves what are called circadian rhythms, which are found in all species with sleep-wake cycles—physical, mental, and behavioral changes that follow a regular schedule. In most animals,…
Read More
A method combining two distinct immune system-based treatments may help to improve outcomes for patients with glioblastomas and other solid tumors. BOSTON – Building on their research showing that an exciting new form of immunotherapy for cancer has activity in patients with glioblastoma, the most common and most deadly form of brain cancer, Massachusetts General Hospital (MGH) investigators have created…
Read More
David A. Braun, MD, PhD, the John R. Svenson Fellow in Oncology at Dana-Farber/Brigham and Women’s Hospital, has been recognized by HemOnc Today as a Next Gen Innovator. This honor is given to early-career hematologists and oncologists who have advanced their field through innovative approaches in clinical and research settings. HemOnc Today’s Next Gen Innovators include clinicians and researchers who specialize in solid…
Read More
The pill is the first known working device capable of non-invasively and accurately assessing the profile of bacterial species inhabiting any stage of the gastrointestinal tract A research team led by Tufts University engineers has developed a 3D printed ingestible pill that samples bacteria found in the gut — known as the microbiome — as it passes through the gastrointestinal…
Read More
MGH will have guaranteed access to ElevateBio BaseCamp’s expert scientists, operators and facilities to accelerate the development of cell and gene therapies for clinical trials MGH makes equity investment in BaseCamp, ElevateBio’s R&D, process development and cGMP manufacturing company BOSTON and CAMBRIDGE, Mass. – July 25, 2019 – Massachusetts General Hospital (MGH) and ElevateBio, a cell and gene therapy holding…
Read More
Abstract Inspired by embryonic wound closure, we present mechanically active dressings to accelerate wound healing. Conventional dressings passively aid healing by maintaining moisture at wound sites. Recent developments have focused on drug and cell delivery to drive a healing process, but these methods are often complicated by drug side effects, sophisticated fabrication, and high cost. Here, we present novel active…
Read More
On its way to being acquired by Bristol-Myers Squibb, Celgene has restructured its three-year-old alliance with Jounce Therapeutics by terminating their up-to-$2.6 billion collaboration to develop multiple cancer immunotherapies, with Celgene instead committing potentially $530 million-plus for global licensing rights to a single Jounce preclinical candidate antibody. The narrower collaboration will see Celgene overseeing all development and commercialization for JTX-8064,…
Read More